# TRAIN-2 (NCT01996267)

> Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01996267
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Breast Cancer; HER2 Positive
- Interventions: PTC+Pertuzumab; FEC-T+Pertuzumab
- Enrollment: 437
- Primary outcome: Number of patients with pathological complete response

## Commentary we found

- YouTube: 12
- Podcasts: 6
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=train-2-nct01996267

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01996267", "email": "<work email>"}; the inbox owner confirms by the emailed link.